Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up.

ABSTRACT:

Background

Noninvasive prenatal screening (NIPS) by next-generation sequencing of cell-free DNA (cfDNA) in maternal plasma is used to screen for common aneuploidies such as trisomy 21 in high risk pregnancies. NIPS can identify fetal genomic microdeletions; however, sensitivity and specificity have not been systematically evaluated. Commercial companies have begun to offer expanded panels including screening for common microdeletion syndromes such as 22q11.2 deletion (DiGeorge syndrome) without reporting the genomic coordinates or whether the deletion is maternal or fetal. Here we describe a phenotypically normal mother and fetus who tested positive for atypical 22q deletion via maternal plasma cfDNA testing.

Methods

We performed cfDNA sequencing on saved maternal plasma obt

SUBMITTER: Yatsenko SA 

PROVIDER: S-EPMC4496325 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature